title: NF-κB Signaling Pathway Inhibitors as Anticancer Drug Candidates.
abstract: Cancer incidence represents an important public health problem worldwide. Nuclear factor kappa B (NF- κB) transcription factor plays a pivotal role in the regulation of genes that control various responses in eukaryotic cells, including proliferation and survival, cytoskeletal remodeling, cellular adhesion and apoptosis. Extensive studies have demonstrated the contribution of NF-κB transcription in the promotion and progression of several hematological malignancies and solid tumors, in which NF-κB constitutive activation and/or overexpression are common clinical features. Moreover, triggering the NF-κB pathway is already considered one of the important mechanisms of resistance development to chemotherapy and radiotherapy, indicating that the inhibition of this signaling cascade is a promising approach to enhancing efficacy and preventing acquired resistance in cancer treatment. In this review, research efforts dedicated to the identification of novel NF-κB signaling pathway inhibitors as promising anticancer drug candidates are described.
authors.affiliation: Laboratorio de Sintese Organica e Quimica Medicinal (LaSOQuiM), Faculdade de Farmacia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ. Brazil.
authors.forename: Maria Letícia
authors.initials: ML
authors.lastname: de Castro Barbosa
authors.affiliation: Laboratorio de Sintese Organica e Quimica Medicinal (LaSOQuiM), Faculdade de Farmacia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ. Brazil.
authors.forename: Raissa Alves
authors.initials: RA
authors.lastname: da Conceicao
authors.affiliation: Laboratorio de Sintese Organica e Quimica Medicinal (LaSOQuiM), Faculdade de Farmacia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ. Brazil.
authors.forename: Aline Guerra Manssour
authors.initials: AGM
authors.lastname: Fraga
authors.affiliation: Laboratorio de Bioensaios Farmaceuticos (LaBioFar), Faculdade de Farmacia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ. Brazil.
authors.forename: Barbara Dias
authors.initials: BD
authors.lastname: Camarinha
authors.affiliation: Laboratorio de Bioensaios Farmaceuticos (LaBioFar), Faculdade de Farmacia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ. Brazil.
authors.forename: Gabriela Cristina
authors.initials: GC
authors.lastname: de Carvalho Silva
authors.affiliation: Laboratorio de Bioensaios Farmaceuticos (LaBioFar), Faculdade de Farmacia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ. Brazil.
authors.forename: Antonio Gilcler Ferreira
authors.initials: AGF
authors.lastname: Lima
authors.affiliation: Laboratorio de Bioensaios Farmaceuticos (LaBioFar), Faculdade de Farmacia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ. Brazil.
authors.forename: Elisama Azevedo
authors.initials: EA
authors.lastname: Cardoso
authors.affiliation: Faculty of Pharmacy, Federal University of Rio de Janeiro, Carlos Chagas Filho Av., 373, ZIP: 21.941-902, Rio de Janeiro. Brazil.
authors.forename: Viviane
authors.initials: V
authors.lastname: de Oliveira Freitas Lione
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology*; D005938:Glucocorticoids / Q000494:pharmacology; D006801:Humans; D051550:I-kappa B Kinase / Q000037:antagonists & inhibitors; D016328:NF-kappa B / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects*; D054875:Ubiquitination / Q000187:drug effects
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000970:Antineoplastic Agents; D005938:Glucocorticoids; D016328:NF-kappa B; D051550:I-kappa B Kinase; D046988:Proteasome Endopeptidase Complex
keywords: NF-κB inhibitor; Nuclear Factor kappa B; antitumor; cancer; drug; transcription factor